5am partners llc - direct investment history in Kalobios pharmaceuticals inc

Filed on 2013-02-07 by 5am Partners Llc SEC CIK 1555951 Form 4

Accession 0001181431-13-007801.txt Sec File: edgar/data/1555951/0001181431-13-007801-index.htm

2013-02-05 5am Partners Llc (CIK 1555951) through Direct

Invested in Kalobios Pharmaceuticals Inc sold 96612 shares at $0 remaining shares owned 0

Series D Preferred Stock Kalobios Pharmaceuticals Inc Kbio underlying security shares 109932.1 underlying security title Common Stock

f7 reflects 1-for-3.56147 reverse stock split which became effective on january 15, 2013.
f12 the shares are held as follows: approximately 96,349.3 shares by ventures and approximately 13,582.8 shares by co-investors. fractional shares were rounded as described in footnote 1 of this form 4.
f5 each share of series d preferred stock automatically converted into approximately 1.14 shares of common stock, including applicable anti-dilution adjustments, in connection with the consummation of issuer's initial public offering.
f8 no expiration date.


Filed on 2013-02-07 by 5am Partners Llc SEC CIK 1555951 Form 4

Accession 0001181431-13-007801.txt Sec File: edgar/data/1555951/0001181431-13-007801-index.htm

2013-02-05 5am Partners Llc (CIK 1555951) through Direct

Invested in Kalobios Pharmaceuticals Inc sold 79886 shares at $0 remaining shares owned 0

Series C Preferred Stock Kalobios Pharmaceuticals Inc Kbio underlying security shares 87434.2 underlying security title Common Stock

f7 reflects 1-for-3.56147 reverse stock split which became effective on january 15, 2013.
f11 the shares are held as follows: approximately 76,631.6 shares by ventures and approximately 10,802.6 shares by co-investors. fractional shares were rounded as described in footnote 1 of this form 4.
f4 each share of series c preferred stock automatically converted into approximately 1.09 shares of common stock, including applicable anti-dilution adjustments, in connection with the consummation of issuer's initial public offering.
f8 no expiration date.


Filed on 2013-02-07 by 5am Partners Llc SEC CIK 1555951 Form 4

Accession 0001181431-13-007801.txt Sec File: edgar/data/1555951/0001181431-13-007801-index.htm

2013-02-05 5am Partners Llc (CIK 1555951) through Direct

Invested in Kalobios Pharmaceuticals Inc sold 175488 shares at $0 remaining shares owned 0

Series B-2 Preferred Stock Kalobios Pharmaceuticals Inc Kbio underlying security shares 175488 underlying security title Common Stock

f7 reflects 1-for-3.56147 reverse stock split which became effective on january 15, 2013.
f10 the shares are held as follows: 153,552 shares by ventures and 21,936 shares by co-investors.
f3 each share of series b-2 preferred stock automatically converted into one share of common stock in connection with the consummation of issuer's initial public offering.
f8 no expiration date.


Filed on 2013-02-07 by 5am Partners Llc SEC CIK 1555951 Form 4

Accession 0001181431-13-007801.txt Sec File: edgar/data/1555951/0001181431-13-007801-index.htm

2013-02-05 5am Partners Llc (CIK 1555951) through Direct

Invested in Kalobios Pharmaceuticals Inc sold 125185 shares at $0 remaining shares owned 0

Series B-1 Preferred Stock Kalobios Pharmaceuticals Inc Kbio underlying security shares 125185 underlying security title Common Stock

f7 reflects 1-for-3.56147 reverse stock split which became effective on january 15, 2013.
f9 the shares are held as follows: 109,537 shares by ventures and 15,648 shares by co-investors.
f2 each share of series b-1 preferred stock automatically converted into one share of common stock in connection with the consummation of issuer's initial public offering.
f8 no expiration date.


Filed on 2013-02-07 by 5am Partners Llc SEC CIK 1555951 Form 4

Accession 0001181431-13-007801.txt Sec File: edgar/data/1555951/0001181431-13-007801-index.htm

2013-02-05 5am Partners Llc (CIK 1555951) through Direct

Invested in Kalobios Pharmaceuticals Inc bought 498038 shares remaining shares owned 721228

Common Stock Kalobios Pharmaceuticals Inc Kbio Transaction code: C Conversion of derivative security (usually options)

f1 represents the sum of all converted shares described in table ii of this form 4. the converted shares were first aggregated on a per reporting person basis and then rounded down to the next whole share. the shares are held as follows: 436,069 shares by 5am ventures llc ("ventures") and 61,969 shares by 5am co-investors llc ("co-investors"). 5am partners llc is the general partner of ventures and co-investors. the managing directors of 5am partners llc are dr. john d. diekman and andrew j. schwab.
f2 each share of series b-1 preferred stock automatically converted into one share of common stock in connection with the consummation of issuer's initial public offering.
f3 each share of series b-2 preferred stock automatically converted into one share of common stock in connection with the consummation of issuer's initial public offering.
f4 each share of series c preferred stock automatically converted into approximately 1.09 shares of common stock, including applicable anti-dilution adjustments, in connection with the consummation of issuer's initial public offering.
f5 each share of series d preferred stock automatically converted into approximately 1.14 shares of common stock, including applicable anti-dilution adjustments, in connection with the consummation of issuer's initial public offering.
f6 the shares are held as follows: 631,418 shares by ventures and 89,810 shares by co-investors.


Filed on 2013-02-04 by 5am Co Investors Llc SEC CIK 1215737 Form 4

Accession 0001181431-13-006519.txt Sec File: edgar/data/1215737/0001181431-13-006519-index.htm

2013-01-31 5am Partners Llc (CIK 1555951) through Direct

Invested in Kalobios Pharmaceuticals Inc bought 62500 shares at $8 remaining shares owned 223190

Common Stock Kalobios Pharmaceuticals Inc Kbio Transaction code: P Open market or private purchase of securities

f1 the shares were acquired as follows: 54,745 shares by 5am ventures llc ("ventures") and 7,755 shares by 5am co-investors llc ("co-investors").
f2 reflects 1-for-3.56147 reverse stock split which became effective on january 15, 2013.
f3 the shares are held as follows: 195,349 shares ventures and 27,841 shares by co-investors. 5am partners llc is the general partner of ventures and co-investors. the managing directors of 5am partners llc are dr. john d. diekman and andrew j. schwab.


Filed on 2012-08-10 by 5am Co Investors Llc SEC CIK 1215737 Form 3

Accession 0001181431-12-045026.txt Sec File: edgar/data/1215737/0001181431-12-045026-index.htm

2012-08-11 5am Partners Llc (CIK 1555951) through Direct

Invested in Kalobios Pharmaceuticals Inc remaining shares owned 572295

Common Stock Kalobios Pharmaceuticals Inc None

f1 the shares are held as follows: 500,758 shares by 5am ventures llc ("ventures") and 71,537 shares by 5am co-investors llc ("co-investors"). 5am partners llc is the general partner of ventures and co-investors. the managing directors of 5am partners llc are dr. john d. diekman and andrew j. schwab.